Human soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation

Scandinavian Journal of Immunology

Volumn 66, Issue 5, 2007, Pages 529-537

  Kakoulidou, M ^b   Giscombe, R ^b   Zhao, X ^b   Lefvert, A K ^b   Wang, X ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; RECOMBINANT PROTEIN; RECOMBINANT SOLUBLE CD80; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; B LYMPHOCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INHIBITION KINETICS; ISOLATION PROCEDURE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ALTERNATIVE SPLICING; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; BASE SEQUENCE; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 35348940179     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02009.x     Document Type: Article

References (51)

1. Collins AV, Brodie DW, Gilbert RJ et al. The interaction properties of costimulatory molecules revisited. Immunity 2002 17 : 201 10.
2. Fleischer J, Soeth E, Reiling N, Grage-Griebenow E, Flad HD, Ernst M. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology 1996 89 : 592 8.
3. Hutchings A, Purcell WM, Benfield MR. Peripheral blood antigen-presenting cells from African-Americans exhibit increased CD80 and CD86 expression. Clin Exp Immunol 1999 118 : 247 52.
4. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989 143 : 2714 22.
5. Vasu C, Wang A, Gorla SR, Kaithamana S, Prabhakar BS, Holterman MJ. CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties. Int Immunol 2003 15 : 167 75.
6. Peach RJ, Bajorath J, Naemura J et al. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J Biol Chem 1995 270 : 21181 7.
7. Yang S, Sim GK. New forms of dog CD80 and CD86 transcripts that encode secreted B7 molecules. Immunogenetics 1999 50 : 349 53.
8. Borriello F, Oliveros J, Freeman GJ, Nadler LM, Sharpe AH. Differential expression of alternate mB7-2 transcripts. J Immunol 1995 155 : 5490 7.
9. Guo Y, Wu Y, Zhao M, Kong XP, Liu Y. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J Exp Med 1995 181 : 1345 55.
10. Inobe M, Linsley PS, Ledbetter JA, Nagai Y, Tamakoshi M, Uede T. Identification of an alternatively spliced form of the murine homologue of B7. Biochem Biophys Res Commun 1994 200 : 443 9.
11. Faas SJ, Giannoni MA, Mickle AP et al. Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1. J Immunol 2000 164 : 6340 8.
12. Hock B, Starling G, Patton W et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 2004 45 : 2111 8.
13. Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005 44 : 989 94.
14. Ip WK, Wong CK, Leung TF, Lam CW. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int Arch Allergy Immunol 2005 137 : 45 52.
15. Freeman GJ, Lombard DB, Gimmi CD et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992 15 : 149.
16. Hock BD, McKenzie JL, Patton WN et al. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003 15 : 98.
17. Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, McKenzie JL. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 2002 16 : 865 73.
18. Shi HZ, Xie ZF, Deng JM, Chen YQ, Xiao CQ. Soluble CD86 protein in serum samples of patients with asthma. Thorax 2004 59 : 870 5.
19. Hebbar M, Jeannin P, Magistrelli G et al. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol 2004 136 : 388 92.
20. Wang XB, Kakoulidou M, Giscombe R et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002 130 : 224 32.
21. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000 15 : 164.
22. Sato S, Fujimoto M, Hasegawa M et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004 43 : 1261 6.
23. Liu MF, Wang CR, Chen PC, Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol 2003 57 : 568 72.
24. Hock BD, Starling GC, Patton WN et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 2004 45 : 2111 8.
25. Andersson J, Sjoberg O, Moller G. Induction of immunoglobulin and antibody synthesis in vitro by lipopolysaccharides. Eur J Immunol 1972 2 : 349 53.
26. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004 75 : 163 89.
27. Bugeon L, Hargreaves RE, Crompton T et al. Selective silencing of full-length CD80 but not IgV-CD80 leads to impaired clonal deletion of self-reactive T cells and altered regulation of immune responses. Eur J Immunol 2001 31 : 118 27.
28. Dwyer JM, Johnson C. The use of concanavalin A to study the immunoregulation of human T cells. Clin Exp Immunol 1981 46 : 237 49.
29. Vahlenkamp TW, Bull ME, Dow JL et al. B7+CTLA4+ T cells engage in T-T cell interactions that mediate apoptosis: a model for lentivirus-induced T cell depletion. Vet Immunol Immunopathol 2004 98 : 203 14.
30. Abe K, Takasaki Y, Ushiyama C et al. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. J Clin Immunol 1999 19 : 58 66.
31. Kochli C, Wendland T, Frutig K, Grunow R, Merlin S, Pichler WJ. CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunol Lett 1999 65 : 197 201.
32. Azuma M, Yssel H, Phillips JH, Spits H, Lanier LL. Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med 1993 1 : 177.
33. Sabzevari H, Kantor J, Jaigirdar A et al. Acquisition of CD80 (B7-1) by T cells. J Immunol 2001 166 : 2505 13.
34. Tatari-Calderone Z, Semnani RT, Nutman TB, Schlom J, Sabzevari H. Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J Immunol 2002 1 : 169.
35. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol 2004 1 : 172.
36. Fargeas CA, Truneh A, Reddy M, Hurle M, Sweet R, Sekaly RP. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4. J Exp Med 1995 1 : 182.
37. Ellis JH, Burden MN, Vinogradov DV, Linge C, Crowe JS. Interactions of CD80 and CD86 with CD28 and CTLA4. J Immunol 1996 15 : 156.
38. Chen A, Meyerson HJ, Salvekar A, Tykocinski ML. Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors. FEBS Lett 1998 29 : 428.
39. Ma BY, Mikolajczak SA, Yoshida T, Yoshida R, Kelvin DJ, Ochi A. CD28 T cell costimulatory receptor function is negatively regulated by N-linked carbohydrates. Biochem Biophys Res Commun 2004 23 : 317.
40. Deshpande M, Venuprasad K, Parab PB, Saha B, Mitra D. A novel CD28 mRNA variant and simultaneous presence of various CD28 mRNA isoforms in human T lymphocytes. Hum Immunol 2002 63 : 20 3.
41. Galea-Lauri J, Darling D, Gan SU et al. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. J Immunol 1999 1 : 163.
42. Deurloo DT, van Berkel MA, van Esch BC et al. CD28/CTLA4 double deficient mice demonstrate crucial role for B7 co-stimulation in the induction of allergic lower airways disease. Clin Exp Allergy 2003 33 : 1297 304.
43. Mandelbrot DA, Oosterwegel MA, Shimizu K et al. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest 2001 107 : 881 7.
44. Gerstmayer B, Hoffmann M, Altenschmidt U, Wels W. Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein. Cancer Immunol Immunother 1997 45 : 156 8.
45. Broeren CP, Gray GS, Carreno BM, June CH. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. J Immunol 2000 15 : 165.
46. Shen W, Wang Y, Geng Y, Si L. Bacterially produced human B7-1 protein encompassing its complete extracellular domain maintains its costimulatory activity in vitro. Chin Med J (Engl) 2000 113 : 714 9.
47. Sturmhoefel K, Lee K, Gray GS et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res 1999 1 : 59.
48. Goetz M, Behre G, Heussel G et al. Soluble tumor necrosis factor receptor type II in the early diagnosis of fever in neutropenia. Ann Hematol 2002 81 : 382 5.
49. Kumar H, Heer K, Greenman J, Kerin MJ, Monson JR. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002 22 : 1877 80.
50. Romero-Adrian T, Ruiz A, Molina-Vilchez R, Estevez J, Atencio R. Interleukin-2 receptor serum concentrations in normal pregnancy and pre- eclampsia. Invest Clin 2002 43 : 73 8.
51. Zinser E, Lechmann M, Golka A, Lutz MB, Steinkasserer A. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med 2004 2 : 200.